Tomáš Seeman1, Ondřej Hradský2, Jiří Gilík3. 1. Department of Pediatrics, Second Medical School, University Hospital Motol, Charles University Prague, V Úvalu 84, 15006, Prague, Czech Republic. tomas.seeman@lfmotol.cuni.cz. 2. Department of Pediatrics, Second Medical School, University Hospital Motol, Charles University Prague, V Úvalu 84, 15006, Prague, Czech Republic. 3. Kardiocentrum and Centre for Cardiovascular Research, University Hospital Motol, Prague, Czech Republic.
Abstract
UNLABELLED: The aim of our study was to investigate whether nocturnal blood pressure (BP) dip is associated with increased left ventricular mass index and hypertrophy in children with hypertension (HT). We retrospectively reviewed data from all children with confirmed ambulatory HT in our center and performed ambulatory blood pressure monitoring (ABPM) and echocardiography at the same time. Left ventricular hypertrophy (LVH) was defined as left ventricular mass index (LVMI) ≥95th centile. Non-dipping phenomenon was defined as nocturnal BP dip <10 %. A total of 114 ABPM studies were included, the median age of children was 15.3 years (3.8-18.9), 80 children had renoparenchymal HT without end-stage renal failure, 34 had primary HT, and 27 studies were done on untreated children and 87 on treated children. Non-dipping phenomenon was present in 63 (55 %) studies (non-dippers). The LVMI adjusted for age was not significantly different between non-dippers and dippers (0.87 ± 0.03 vs. 0.81 ± 0.02, p = 0.13). Left ventricular hypertrophy was not significantly higher in non-dippers than in dippers (20 vs. 9 %, p = 0.12). CONCLUSION: Hypertensive children without end-stage renal failure with non-dipping phenomenon do not have increased prevalence of LVH or higher LVMI adjusted for age than hypertensive children with preserved nocturnal BP dip. WHAT IS KNOWN: • Adult and pediatric hypertensive patients with end-stage renal failure have often nocturnal blood pressure non-dipping phenomenon. • Non-dipping phenomenon is in patients with end-stage renal failure associated with increased prevalence of left ventricular hypertrophy. What is New: • Pediatric hypertensive patients without end-stage renal failure with blood pressure non-dipping phenomenon do not have increased prevalence of left ventricular hypertrophy.
UNLABELLED: The aim of our study was to investigate whether nocturnal blood pressure (BP) dip is associated with increased left ventricular mass index and hypertrophy in children with hypertension (HT). We retrospectively reviewed data from all children with confirmed ambulatory HT in our center and performed ambulatory blood pressure monitoring (ABPM) and echocardiography at the same time. Left ventricular hypertrophy (LVH) was defined as left ventricular mass index (LVMI) ≥95th centile. Non-dipping phenomenon was defined as nocturnal BP dip <10 %. A total of 114 ABPM studies were included, the median age of children was 15.3 years (3.8-18.9), 80 children had renoparenchymal HT without end-stage renal failure, 34 had primary HT, and 27 studies were done on untreated children and 87 on treated children. Non-dipping phenomenon was present in 63 (55 %) studies (non-dippers). The LVMI adjusted for age was not significantly different between non-dippers and dippers (0.87 ± 0.03 vs. 0.81 ± 0.02, p = 0.13). Left ventricular hypertrophy was not significantly higher in non-dippers than in dippers (20 vs. 9 %, p = 0.12). CONCLUSION:Hypertensivechildren without end-stage renal failure with non-dipping phenomenon do not have increased prevalence of LVH or higher LVMI adjusted for age than hypertensivechildren with preserved nocturnal BP dip. WHAT IS KNOWN: • Adult and pediatric hypertensivepatients with end-stage renal failure have often nocturnal blood pressure non-dipping phenomenon. • Non-dipping phenomenon is in patients with end-stage renal failure associated with increased prevalence of left ventricular hypertrophy. What is New: • Pediatric hypertensivepatients without end-stage renal failure with blood pressure non-dipping phenomenon do not have increased prevalence of left ventricular hypertrophy.
Authors: Tomás Seeman; Eva Simková; Jirí Kreisinger; Karel Vondrák; Jirí Dusek; Jirí Gilík; Janusz Feber; Pavel Dvorák; Jan Janda Journal: Pediatr Transplant Date: 2006-05
Authors: Mark M Mitsnefes; Thomas R Kimball; Janis Kartal; Sandra A Witt; Betty J Glascock; Philip R Khoury; Stephen R Daniels Journal: J Pediatr Date: 2006-11 Impact factor: 4.406
Authors: C Cuspidi; I Michev; S Meani; B Severgnini; V Fusi; C Corti; M Salerno; C Valerio; F Magrini; A Zanchetti Journal: J Hum Hypertens Date: 2003-04 Impact factor: 3.012
Authors: Christine Y Bakhoum; Ronit Katz; Joshua A Samuels; Tala Al-Rousan; Susan L Furth; Joachim H Ix; Pranav S Garimella Journal: Clin J Am Soc Nephrol Date: 2021-11-12 Impact factor: 8.237
Authors: Brooks B Gump; Kevin S Heffernan; Kestutis Bendinskas; Bryce Hruska; James A MacKenzie; Aesoon Park; Lynn S Brann; Nader H Atallah-Yunes Journal: Psychosom Med Date: 2021-04-01 Impact factor: 3.864
Authors: Lucy J Goudswaard; Sean Harrison; Daniel Van De Klee; Nishi Chaturvedi; Debbie A Lawlor; George Davey Smith; Alun D Hughes; Laura D Howe Journal: PLoS One Date: 2021-06-16 Impact factor: 3.240